Johnson & Johnson is boosting its pipeline, announcing Monday a $2.2 billion agreement to buy Ollin Biosciences, a clinical-stage startup whose lead drug candidate could introduce competition to a blockbuster Roche vision disorders product.
The Ollin drug, OLN324, is a bispecific antibody designed to block two pathways, VEGF and Ang2. Those are the same targets hit by Vabysmo, bispecific antibody marketed by Roche. Austin, Texas-based Ollin has claimed its drug could be best in its class.
In a proof-of-concept Phase 1b test that compared OLN324 head to head against Vabysmo, Ollin reported its drug, administered by injection into the eye, led to faster and greater structural changes in the eye and numerically better vision improvement at 20 weeks in both age-related macular degeneration (AMD) and diabetic macular edema (DME), the two indications where Vabysmo has regulatory approvals. OLN324’s Phase 1b results were presented in July during the annual meeting of the American Society of Retina Specialists. In Monday’s acquisition announcement, Kip Connor, vice president, ophthalmology disease area stronghold leader, Johnson & Johnson, said the Ollin drug has the potential to achieve stronger and more sustained disease control.
“The data generated to date are compelling and point to a potentially transformative clinical profile that could deliver more effective reduction of retinal fluid and allow more time between treatments, ultimately redefining what is possible for patients,” Connor said.
Ollin has been gearing up for a Phase 3 clinical test of OLN324 in wet AMD and DME. With the J&J acquisition, the pharma company will take on responsibility for the pivotal trials. J&J has already lined up trial financing. Separate from the Ollin acquisition, Blackstone Life Sciences has agreed to pay up to $750 million for OLN324’s late-stage clinical development in exchange for regulatory and sales milestone payments as well as royalties from sales of an approved product.
Ollin formed in 2023 and formally launched last year, backed by $100 million in financing led by Arch Venture Partners, Mubadala Capital, and Monograph Capital. OLN324 was discovered by China-based Innovent Biologics; Ollin and Innovent collaborated on the drug’s clinical development. This past June, TCGX and Arch co-led a $330 million Series B financing to support Ollin’s Phase 3 tests of OLN324.
J&J’s main presence in vision is through its medical technology business segment, which sells contact lenses and products used in cataract and refractive procedures. The pharma company’s efforts to expand its vision disorders scope to gene therapy fell short. Last year, a gene therapy for X-linked retinitis pigmentosa associated with mutations to the RPGR gene failed its Phase 3 test. MeiraGtx, the therapy’s original developer, reacquired global rights to the asset earlier this year.
The Ollin acquisition will bring a second drug program, OLN102. This bispecific antibody is designed to block TSHR and IGF-1R to treat thyroid eye disorder (TED). OLN102 was discovered by VelaVigo, which has been developing the drug in partnership with Ollin. When Ollin announced its Series B financing, the biotech said its plans included advancing OLN102 into the clinic this year.
Beyond J&J’s $1.2 billion upfront payment to Ollin, the pharma company could pay out up to $1.1 billion more if OLN324 achieves milestones. The companies expect to close the transaction by the end of this year.
Photo: Mario Tama, Getty Images
